Why the SCOTUS’s Gun & Drug Case Matters for Cannabis Businesses
By Alex Hearding, Founder & President – Red Wolf Risk LLC
What’s going on: The Case and Its Implications
The Supreme Court of the United States has granted certiorari in the case of United States v. Hemani, which challenges the constitutionality of Section 922(g)(3) the federal statute preventing anyone who is an “unlawful user of or addicted to any controlled substance” from possessing firearms. Although this case arises in a firearms law context, cannabis businesses, lenders, insurers and risk managers should pay attention, because the framing of “cannabis use” in federal law, and how the government treats state-legal cannabis actors, is under scrutiny.
According to the government’s brief:
DOJ argues that “habitual illegal drug users — including those who use marijuana, cocaine, or other narcotics — pose a grave risk of armed, hostile encounters with police officers while impaired.”
Several appeals courts have already held that the statute’s application to marijuana users raises serious Second Amendment questions.
Why Cannabis-Industry Operators Should Care
1. Federal / State Tension
Many cannabis businesses operate legally under state law, yet this statute treats “unlawful users of … controlled substances” as disqualified from gun possession, regardless of state legal status. If the Court narrows or overturns this law, it may signal greater federal recognition of the distinction between state-legal cannabis actors and unlawful drug users.
2. Insurance, Lending & Risk Signals
For lenders, insurers, and risk managers working with cannabis operators, the way federal law treats cannabis users or their business associates influences underwriting, loan risk, collateral treatment, and compliance perceptions. If marijuana users (even legally) are treated under law as “unlawful drug users,” that raises regulatory risk, and could drive higher premiums or stricter conditions.
3. Narrative & Advocacy Risks
As you’ve flagged in your concerns, the government’s framing lumps cannabis with harder narcotics (cocaine, meth) under the umbrella of “illegal drug use → risk → guns.” Without clear messaging, the cannabis industry could be drawn into an undesirable narrative that reinforces risk rather than resolving it.
Strategic Positioning: How to Think About This
Here are key advocacy/positioning take-aways for cannabis operators, lenders, insurers:
Focus on federalism and overbreadth: The strongest argument isn’t “I use cannabis and should have a gun” but rather “this statute sweeps in persons compliant with state law, undermining federal-state alignment.”
Avoid the ‘drug-user rights’ framing: Don’t position the case as “drug users deserve gun rights.” Instead, frame it as “state-law-compliant cannabis consumers should not be treated the same as traffickers in cocaine or meth.”
Highlight lack of historical analogue: Under New York State Rifle & Pistol Association v. Bruen (2022), any gun regulation must map to historical tradition. Several courts have found § 922(g)(3) lacks such precedent, especially with regard to non-intoxicating or state-legal cannabis use.
Frame this as modernization: The narrative should be “the law needs to reflect modern, state-legal cannabis frameworks — not a loosening of gun laws for drug users per se.”
Why This Could Matter for Cannabis Businesses
Licensing & compliance perceptions: If state-legal cannabis operations are seen as high-risk (on par with trafficking) by federal law, lenders and insurers may factor that into terms. A favorable decision could reduce that stigma.
Collateral & asset risk: Some lending models assume operator possession/control of firearms or security arms — how the law treats cannabis-industry actors might impact underwriting.
Industry advocacy leverage: A decision narrowing § 922(g)(3) could open a broader discussion about federal-state misalignment on cannabis, which could translate into regulatory reforms beneficial to the industry.
Takeaway for Your Business
As someone advising cannabis operators, lenders and insurers:
Monitor this Supreme Court case closely, its outcome may reshape federal risk landscapes for cannabis-industry actors.
Review your underwriting, insurance placement, and risk-analysis assumptions: Are you treating cannabis-operator firearms or security exposures properly given the legal backdrop?
Craft your narrative carefully: When speaking publicly (or co-sponsoring amicus briefs), emphasize state-legal compliance, operational readiness, and modernization, not a general drug-user rights argument.
Use this moment to distinguish cannabis from heavier-risk categories: One of the major gaps in the federal law’s logic is the lack of distinction between cannabis and hard narcotics, that distinction is material and credible for risk assessment.
Alex Hearding is the Founder and President of Red Wolf Risk and has more than 17 years of experience in cannabis operations, risk management, quality systems, and regulatory compliance.
This piece is part of Chronic Risk, the insights publication of Red Wolf Risk. Read the full article, comments, and related essays on the original publication.
Read the full article